MOTS-c Research & Studies
Part of the full MOTS-c guide - a mitochondrial-derived peptide reference compound, identity-verified with a COA on every vial.
In brief
The MOTS-c research record cited in this reference centers on four peer-reviewed papers spanning 2015 to 2021, each probing a different facet of how this mitochondrial-derived peptide behaves in cultured cells and animal-tissue models. Because MOTS-c was only identified in 2015, the literature is comparatively young and tightly clustered around the discovering group and its collaborators. The four provided sources move from the foundational discovery and metabolic characterization, through the molecular dissection of nuclear translocation, to a study of exercise-responsive signaling in animal models, and finally a review situating MOTS-c within the broader family of mitochondrial-derived peptides. What follows summarizes what these specific sources actually investigate and the in-vitro and preclinical model contexts they use, attributed only to the cited works. Nothing here should be read as evidence of clinical benefit; all are mechanistic or model-system studies of peptide signaling.
The detail
A closer look
01
Discovery and metabolic characterization (Lee et al. 2015)
Lee et al. 2015 in Cell Metabolism (PMID 25738459) is the discovery paper. Authored by Changhan Lee in the Pinchas Cohen laboratory at the USC Leonard Davis School of Gerontology, it identified MOTS-c as a peptide encoded by a short ORF within the mitochondrial 12S rRNA (MT-RNR1) region. The study established the peptide's primary signaling node: activation of AMPK via folate-cycle and de novo purine-biosynthesis modulation, with AICAR accumulation acting as the non-canonical, energy-charge-independent trigger. It also reported modulation of insulin-stimulated glucose-uptake pathways in model systems. This source anchors the research areas of AMPK signaling activation and folate/one-carbon metabolism modulation. Its findings are mechanistic observations in cultured cells and rodent tissue models, framed in the reference data as model-system signaling behavior rather than clinical efficacy.
02
Nuclear translocation and transcriptional regulation (Kim et al. 2018)
Kim et al. 2018 in Cell Metabolism (PMID 29983246) investigates where MOTS-c goes under stress and what it does once there. This work characterized the AMPK-dependent translocation of the peptide from cytosol to nucleus during metabolic stress and its interaction with the transcription factor NRF2 at antioxidant-response elements. It is the source behind the research areas of mitonuclear retrograde communication, stress-induced nuclear translocation, and NRF2/ARE-mediated antioxidant transcriptional response in vitro. By showing a mitochondrially encoded peptide occupying nuclear regulatory DNA, this study extended MOTS-c biology from a cytosolic metabolic regulator to a participant in nuclear gene-expression programs, deepening the mitonuclear-crosstalk theme that distinguishes mitochondrial-derived peptides from conventional signaling molecules.
03
Exercise-responsive signaling and MDP biology (Reynolds 2021; Merry 2020)
Reynolds et al. 2021 in Nature Communications (PMID 33473109) examines MOTS-c as an exercise-induced, mitochondrial-encoded regulator connected to muscle homeostasis and age-dependent physical decline, supplying the basis for the skeletal-muscle metabolic gene-expression and exercise-responsive signaling research area in animal models. Merry et al. 2020 in the American Journal of Physiology-Endocrinology and Metabolism (PMID 32543941) is a review of mitochondrial-derived peptides in energy metabolism; it supports the broader MDP-biology and microprotein-discovery research area, placing MOTS-c alongside other peptides encoded within mtDNA. Together these two sources frame MOTS-c within both a tissue-specific signaling context and the wider conceptual field of microprotein discovery, again as preclinical and review-level findings rather than clinical claims.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. MOTS-c is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.